¨
H.-S. M. Siah, C. H. Gorbitz, and L.-L. Gundersen
1378
Vol 48
7.33–7.21 (m, 5H, Ph), 5.35 (s, 2H, CH2); 13C-NMR (75 MHz,
DMSO-d6) d 154.7 (C-6), 153.0 (C-2), 150.9 (C-4), 135.9 (C-
8), 128.7 (Ph), 127.8 (Ph), 127.1 (Ph), 126.5 (Ph), 119.0 (C-5),
46.6 (CH2); ms: m/z 305/303 (26/26, Mþ), 91 (100).
3-Benzyl-8-bromo-3H-purin-6-amine (3). Colorless pow-
dery crystals, m.p. 233–235ꢁC (Lit. [4], 239–240.5ꢁC). 1H-
NMR (300 MHz, DMSO-d6) d 8.53 (s, 1H, H-2), 8.22 (br s,
1H, NH2), 8.10 (br s, 1H, NH2), 7.40–7.29 (m, 5H, Ph), 5.46
(s, 2H, CH2); 13C-NMR (75 MHz, DMSO-d6) d 153.6 (C-6),
149.8 (C-4), 144.0 (C-2), 139.3 (C-8), 135.8 (Ph), 128.7 (Ph),
128.1 (Ph), 127.8 (Ph), 121.5 (C-5), 52.0 (CH2); ms: m/z 305/
303 (28/28, Mþ), 91 (100).
X-ray crystallographic analysis for compound 3. Crystals
of 3 suitable for X-ray crystallography were obtained from a so-
lution of compound 3 in acetonitrile placed inside a larger vial
containing ethyl acetate. They were unstable at room temperature
due to loss of co-crystallized ethyl acetate solvent molecules, and
X-ray data collection with Apex-2 [11] was thus performed at
105 K. Apex II single crystal CCD-diffractometer, MoKa radia-
Acknowledgments. The Norwegian Research Council is greatly
acknowledged for financing of the Bruker Advance DPX 300
and the Bruker AVII 600 instruments used in this study. We
thank Prof. Frode Rise for obtaining the 1H-15N HSQC spectrum
and Matthew L. Read for assistance with crystallization of
compound 3.
REFERENCES AND NOTES
[1] Shaw, G. In Comprehensive Heterocyclic Chemistry; Potts,
K. T., Ed.; Pergamon Press: Oxford, 1984; Vol. 5, pp 499–605.
[2] Meszarosova, K.; Holy, A.; Masojidkova, M. Collect Czech
Chem Commun 2000, 65, 1109.
[3] Janeba, Z.; Holy, A.; Masojidkova, M. Collect Czech Chem
Commun 2000, 65, 1126.
[4] Havelkova, M.; Dvorak, D.; Hocek, M. Synthesis 2001,
1704.
[5] Li, X.; Vince, R. Bioorg Med Chem 2006, 14, 5742.
[6] Krouzelka, J.; Linhart, I.; Tobrman, T. J Heterocycl Chem
2008, 45, 789.
˚
tion (k ¼ 0.71069 A), 0.30 mm ꢃ 0.30 mm ꢃ 0.26 mm block-
shaped specimen, data integration and cell refinement with
SAINT-Plus [12], absorption correction by SADABS [13], struc-
ture solution by and least-squares refinement on F2 with
SHELXTL [14]. Solvent molecules are located on two different
inversion centers, each with a maximum allowed occupancy of
0.500 and form distinct channels running through the crystal
along the ab-diagonal. The geometries of independent solvent
molecules were constrained to be similar within a standard devia-
[7] Krouzelka, J.; Linhart, I. Heterocycles 2009, 78, 1205.
[8] Allen, F. H. Acta Crystallogr Sect B 2002, 58, 380.
[9] Glu¨senkamp, K.-H.; Kru¨ger, K.; Eberle, G.; Drosdziok, W.;
¨
¨
Jahde, E.; Grundel, O.; Neuhaus, A.; Boese, R.; Stellberg, P.; Rajew-
sky, M. F. Angew Chem Int Ed Engl 1993, 32, 1640.
[10] Bakkestuen, A. K.; Gundersen, L.-L.; Petersen, D.; Ute-
nova, B. T.; Vik, A. Org Biol Chem 2005, 3, 1025.
[11] Bruker AXS, Inc. APEX2; Bruker AXS, Inc.: Madison,
Wisconsin, USA, 2007.
˚
˚
tion of 0.002 A for bond lengths and 0.003 A for 1–3 distances.
3-Benzyl-8-bromo-3H-purin-6-amine ethyl acetate solvate:
C12H10BrN5ꢂ0.5C4H8O2, M ¼ 348.21, triclinic, P1, a ¼ 8.4937(6)
[12] Bruker AXS, Inc. SAINT-Plus; Bruker AXS, Inc.: Madison,
Wisconsin, USA, 2007.
ꢁ
˚
˚
˚
A, b ¼ 12.9096(9) A, c ¼ 15.2238(10) A, a ¼ 101.723(1) , b ¼
105.162(1)ꢁ, c ¼ 108.192(1)ꢁ, Z ¼ 4, Nobserved ¼ 5830, R[F2 >
2r(F2)] ¼ 0.058, wR(F2) ¼ 0.146, CCDC 786213.
[13] Bruker AXS, Inc. SADABS; Bruker AXS, Inc.: Madison,
Wisconsin, USA, 2007.
[14] Sheldrick, G. M. Acta Crystallogr Sect A 2008, 64, 112.
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet